MX2015010296A - Tratamiento de formas progresivas de esclerosis multiple con laquinimod. - Google Patents
Tratamiento de formas progresivas de esclerosis multiple con laquinimod.Info
- Publication number
- MX2015010296A MX2015010296A MX2015010296A MX2015010296A MX2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A
- Authority
- MX
- Mexico
- Prior art keywords
- laquinimod
- multiple sclerosis
- human subject
- treating
- treatment
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 230000000750 progressive effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/016278 WO2014127139A1 (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010296A true MX2015010296A (es) | 2016-05-05 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010296A MX2015010296A (es) | 2013-02-15 | 2014-02-13 | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (https=) |
| EP (1) | EP2956137A4 (https=) |
| JP (1) | JP2016510343A (https=) |
| KR (1) | KR20150119227A (https=) |
| CN (1) | CN105163737A (https=) |
| AU (1) | AU2014216199A1 (https=) |
| BR (1) | BR112015019564A2 (https=) |
| CA (1) | CA2900503A1 (https=) |
| CL (1) | CL2015002181A1 (https=) |
| EA (1) | EA201591507A1 (https=) |
| HK (2) | HK1218254A1 (https=) |
| IL (1) | IL240014A0 (https=) |
| MX (1) | MX2015010296A (https=) |
| PE (1) | PE20151526A1 (https=) |
| SG (1) | SG11201505818WA (https=) |
| TW (1) | TW201442709A (https=) |
| UY (1) | UY35328A (https=) |
| WO (1) | WO2014127139A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN114699409A (zh) * | 2014-10-16 | 2022-07-05 | 诺华股份有限公司 | 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合 |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) * | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| US20230296628A1 (en) * | 2020-07-09 | 2023-09-21 | Oklahoma Medical Research Foundation | Biomarkers for Identifying Relapses in Multiple Sclerosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8138201B2 (en) * | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US20110268699A1 (en) * | 2008-12-11 | 2011-11-03 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| AU2011338647A1 (en) * | 2010-12-07 | 2013-07-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| AU2012286701A1 (en) * | 2011-07-28 | 2014-03-06 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
-
2014
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UY35328A (es) | 2014-09-30 |
| CN105163737A (zh) | 2015-12-16 |
| EA201591507A1 (ru) | 2015-12-30 |
| HK1218251A1 (zh) | 2017-02-10 |
| EP2956137A1 (en) | 2015-12-23 |
| CA2900503A1 (en) | 2014-08-21 |
| WO2014127139A1 (en) | 2014-08-21 |
| BR112015019564A2 (pt) | 2017-07-18 |
| SG11201505818WA (en) | 2015-08-28 |
| US20140235670A1 (en) | 2014-08-21 |
| CL2015002181A1 (es) | 2016-06-03 |
| HK1218254A1 (zh) | 2017-02-10 |
| TW201442709A (zh) | 2014-11-16 |
| IL240014A0 (en) | 2015-09-24 |
| KR20150119227A (ko) | 2015-10-23 |
| PE20151526A1 (es) | 2015-11-20 |
| AU2014216199A1 (en) | 2015-09-03 |
| US20180064702A1 (en) | 2018-03-08 |
| EP2956137A4 (en) | 2016-08-03 |
| JP2016510343A (ja) | 2016-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA033374B9 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| PH12012501741A1 (en) | Treatment of lupus arthritis using laquinimod | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| PH12012501740A1 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| TW201613583A (en) | Laquinimod for the treatment of relapsing- remitting multiple sclerosis (RRMS) patients with a high disability status | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| GEP20207145B (en) | Combination of trazodone and gabapentin for the treatmen | |
| MX2016001179A (es) | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| AR094809A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod |